Trial Site Detail
Drug: |
CB-839 |
|||
|---|---|---|---|---|
Trial: |
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Active, not recruiting |
|||
Robert Lurie Comp. Cancer Center Northwestern University Hospital675 North St. Clair |
Principal Investigator: |
|
|---|---|
Contact: |
|
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Robert Lurie Comp. Cancer Center Northwestern University Hospital Website: |
http://www.cancer.northwestern.edu/public/why_northwestern/clinical_trials/index.cfm |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.